CDKN2A纯合缺失在IDH突变低级别胶质瘤和胶质母细胞瘤中的预后意义:当代文献系统综述
该系统综述基于PRISMA指南检索7个数据库至2020年2月,纳入9项机构研究共2193例IDH突变胶质瘤(低级别胶质瘤1756例,胶质母细胞瘤437例)。Kaplan-Meier分析显示CDKN2A纯合缺失与低级别胶质瘤和胶质母细胞瘤的无进展生存期和总生存期缩短相关,多变量分析证实其为独立不良预后因素。
要点
- CDKN2A纯合缺失在IDH突变胶质瘤中发生率9-43%,中位22%。
- 低级别胶质瘤中缺失者中位PFS 31 vs 91个月,OS 61 vs 154个月。
- 胶质母细胞瘤中缺失者中位PFS 16 vs 30个月,OS 38 vs 86个月。
核心结论
- CDKN2A纯合缺失是IDH突变胶质瘤患者生存结局的重要预后因素,跨越多个WHO组织学分级。
研究设计与样本
- 遵循PRISMA指南系统检索7个电子数据库自建库至2020年2月,纳入9项机构研究共2193例IDH突变胶质瘤。
主要发现
- 低级别胶质瘤中CDKN2A纯合缺失者中位PFS为31个月 vs 91个月(三项研究),中位OS为61个月 vs 154个月(五项研究)。
- 胶质母细胞瘤中CDKN2A纯合缺失者中位PFS为16个月 vs 30个月(两项研究),中位OS为38个月 vs 86个月(四项研究)。
- 多变量分析显示CDKN2A纯合缺失是低级别胶质瘤和胶质母细胞瘤中PFS和OS显著缩短的预测因素。
关键数值与推荐
- CDKN2A纯合缺失在IDH突变胶质瘤中的比例范围为9-43%,中位发生率为22%。
临床怎么用
- 识别CDKN2A纯合缺失有助于对IDH突变胶质瘤患者进行风险分层和优化管理。
局限性
- 需进一步理解如何利用该缺失指导治疗分层以优化临床病程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The most recent cIMPACT-NOW update highlighted the homozygous deletion of the Cyclin Dependent Kinase Inhibitor 2A (CDKN2A) gene as a clinically important molecular alteration in IDH-mutant glioma. Correspondingly, we systematically reviewed the contemporary literature to affirm the contemporary stance of the literature on the prognostic significance of this alteration in this setting based on the current World Health Organization (WHO) Grade classification. METHODS: A systematic search of seven electronic databases from inception to February 2020 was conducted following PRISMA guidelines. Articles were screened against pre-specified criteria to include lower-grade glioma (LGG, WHO Grade II/III) and glioblastoma (GBM, WHO Grade IV) separately. Progression free survival (PFS) and overall survival (OS) from Kaplan-Meier and multivariable analyses were outcomes of interest. RESULTS: Nine institutional studies describing 2193 IDH-mutant gliomas satisfied criteria for evaluation, with 1756 (80%) LGG and 437 (20%) GBM. When reported, the proportion of CDKN2A homozygous deleted gliomas ranged from 9 to 43%, with a median incidence of 22%. For LGG, Kaplan-Meier analyses demonstrated shorter PFS in the presence of CDKN2A homozygous deletion in three studies (median values, 31 versus 91 months), and shorter OS in five studies (median values, 61 versus 154 months). For GBM, Kaplan-Meier analyses demonstrated shorter PFS in the presence of CDKN2A homozygous deletion in two studies (median values, 16 versus 30 months), and shorter OS in four studies (median values, 38 versus 86 months). By multivariable analyses, CDKN2A homozygous deletion was a predictor of significantly shorter PFS and OS in both LGG and GBM across all included studies. CONCLUSIONS: The CDKN2A homozygous deletion is an important prognostic factor for survival outcomes of IDH-mutant glioma patients across multiple histologic WHO grades with specific molecular features likely dependent on IDH-mutant status. Greater understanding of how identifying this deletion can assist in the stratification of management for these tumors to optimize clinical course is required.
引用
- Lu VM, O'Connor KP, Shah AH, et al. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature. J Neurooncol. 2020. PMID: 32385699. doi:10.1007/s11060-020-03528-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。